Renew ECP Therapy is a non-surgical treatment that can reduce the debilitating symptoms of stable angina. Extensive research has demonstrated ECP technology as an effective tool to improve micro circulation and vasodilation in people suffering from the effects of heart disease, in particular stable angina. The European Society of Cardiology approved ECP technology and in 2013 upgraded its recommendation, stating that the treatment should be offered to individuals in whom heart bypass surgery or stents are not possible or appropriate. The treatment is for those diagnosed with heart disease and angina, whose condition has not improved with medication, and who are unable to undergo surgery or wish to try a non-invasive alternative to standard treatment options.
Studies have clearly demonstrated chronic stable angina patients who respond well to ECP therapy often experience (1):
Due to the haemodynamic effects of ECP, the benefits apply not only to the heart, but to the entire cardiovascular system. Enhanced blood circulation during the inflation and deflation of cuffs during the therapy, greatly increases shear stress (the frictional force on blood vessels), thereby stimulating production of Nitric Oxide.
Here are some key findings from extensive research into how the integration of ECP therapy can improve the patient quality of life, reduce long term treatment costs and re-hospitalisation.
Other key therapy impacts include:
Significant reduction in rates of ED visits and hospitalisation compared to six month pre-treatment.
Observed and predicted re-admissions rates for 90 days after discharge.